Shield Bio careers

At Shield, we’re ensuring that antibiotic resistance doesn’t become deadlier than cancer.

In 2050 more people will be dying of antibiotic resistant pathogens than cancer. Infections that were once treatable with a simple oral antibiotics are now requiring complex, painful treatments and resulting in serious health implications for patients.

Gonorrhea is one such infection, having become resistant to over 10 different antibiotics, we have only one treatment that is still effective and resistance to this has already begun to occur. With 820,000 new infections every year in the US, antibiotic resistance will spread quickly, which is why the CDC has resistant Gonorrhea at an urgent threat level, the highest level available.

Shield's novel genomic testing platform enables identification of multiple antibiotic resistant strains of gonorrhea and other pathogens so that the most effective antibiotics can be used, helping to slow the pace of antibiotic resistance.